GLP-1 Drugs and SGLT-2 Inhibitors Linked to Lower Liver Cancer and Liver Disease Risk in 5.3 Million Diabetes Patients | Research

The takeaway

In a meta-analysis of over 5.3 million patients with type 2 diabetes, GLP-1 receptor agonists reduced liver cancer risk by 23% and liver-related events by 21%, while DPP-4 inhibitors showed no liver protection.

5.3 million patients
Across 36 studies, GLP-1 receptor agonists reduced liver cancer risk by 23% and were uniquely protective against hepatic decompensation in patients with chronic liver disease

What the researchers found

GLP-1 receptor agonists were associated with a 23% reduction in hepatocellular carcinoma (HCC) risk (HR 0.77, 95% CI 0.66–0.90) and a 21% reduction in non-HCC liver-related events (HR 0.79, 95% CI 0.65–0.95) compared to other glucose-lowering therapies.

SGLT-2 inhibitors showed similar liver protection: 24% reduction in HCC (HR 0.76, 95% CI 0.67–0.86) and 18% reduction in liver-related events (HR 0.82, 95% CI 0.73–0.92).

DPP-4 inhibitors showed no protection against HCC (HR 1.12, 95% CI 0.91–1.39) and were associated with a 24% increased risk of liver-related events (HR 1.24, 95% CI 1.15–1.34).

In patients with chronic liver disease specifically, GLP-1 receptor agonists were uniquely associated with reduced hepatic decompensation (HR 0.79, 95% CI 0.71–0.88).

Why it matters

Liver cancer is the sixth most common cancer and the third leading cause of cancer death globally, and type 2 diabetes significantly increases the risk. This study provides the most comprehensive evidence to date that the choice of diabetes medication matters for liver health. For the millions of diabetic patients also at risk for liver disease, GLP-1 receptor agonists may offer dual protection — managing blood sugar while reducing liver cancer and liver disease risk.

How the study worked

Systematic literature search identified studies reporting hepatic complications in type 2 diabetes patients prescribed GLP-1 RAs, SGLT-2 inhibitors, or DPP-4 inhibitors, compared against other glucose-lowering therapies. From 2,228 records screened, 36 cohort studies comprising 5,363,858 patients were included. Random-effects meta-analyses estimated pooled hazard ratios. Subgroup analyses were conducted for patients with chronic liver disease.

What this study cannot tell us

All 36 included studies were observational cohort studies, not randomized controlled trials, so confounding cannot be fully excluded. The comparator groups varied across studies (different glucose-lowering therapies), which introduces heterogeneity. The analysis could not account for disease duration, medication adherence, or specific drug doses within each class. The DPP-4 inhibitor finding of increased liver-related events may reflect confounding by indication rather than a causal effect.

How to read the evidence

This is a large systematic review and meta-analysis of 36 cohort studies with over 5.3 million patients, published in Hepatology. While the enormous sample size and consistent results are compelling, all included studies are observational (not randomized), which limits causal inference. The strength of the associations and their consistency across studies is notable.

When this study was published

Published in 2026 in Hepatology, this is a very current meta-analysis synthesizing the latest observational evidence. The findings are directly relevant to current clinical practice and ongoing debates about optimal diabetes medication selection.

The bigger picture

This meta-analysis adds liver protection to the growing list of benefits beyond glucose control for GLP-1 receptor agonists, alongside cardiovascular, kidney, and possibly neurological benefits. The sharp contrast between GLP-1 RAs/SGLT-2 inhibitors (protective) and DPP-4 inhibitors (neutral-to-harmful for liver) has important implications for treatment selection in type 2 diabetes, particularly for patients with underlying liver disease or metabolic-associated fatty liver disease (MAFLD).

Questions still open

What are the biological mechanisms by which GLP-1 receptor agonists protect against liver cancer — is it through direct hepatoprotection, weight loss, or metabolic improvement?
Would the liver-protective effects of GLP-1 drugs extend to non-diabetic patients with fatty liver disease?
Should the liver outcome differences between drug classes influence first-line diabetes treatment selection in patients with liver disease risk factors?

Common questions

Which diabetes drugs are best for liver health?

GLP-1 receptor agonists and SGLT-2 inhibitors were both associated with significant reductions in liver cancer and liver-related events. GLP-1 drugs showed an additional unique benefit of reducing hepatic decompensation in patients with existing chronic liver disease. DPP-4 inhibitors showed no liver protection and may increase liver-related event risk.

Should diabetes patients with liver disease switch medications based on this study?

This large meta-analysis suggests that GLP-1 receptor agonists may be particularly beneficial for diabetes patients with liver disease risk factors. However, medication changes should always be discussed with a healthcare provider, as this is observational evidence and individual factors must be considered.

Read the original research

Impact of newer antihyperglycemic agents on hepatic complications: A systematic review and meta-analysis of data from 5.3 million patients with type 2 diabetes mellitus.

Hepatology (Baltimore, Md.)

View on PubMed ↗Publisher’s paper ↗

Citation

Yang, Jiwon; Hwang, Yeongseok; Ju, Jin-Sung; Han, Seungbong; An, Jihyun; Shim, Ju Hyun. (2026). Impact of newer antihyperglycemic agents on hepatic complications: A systematic review and meta-analysis of data from 5.3 million patients with type 2 diabetes mellitus.. Hepatology (Baltimore, Md.). https://doi.org/10.1097/HEP.0000000000001695